Charlotte Parker, Author at Oral Cancer News

Although Most Smokers Want to Quit… Only a Fraction Actually Do

Source: The Wall Street Journal Author: Betsy McKay More than two-thirds of American smokers want to quit, but only a fraction actually do, underscoring a need for more services, messages, and access to medications to help them kick the habit, according to a new government report out today. Nearly 69% of adult smokers wanted to quit in 2010 and more than half tried, but only 6.2% succeeded, according to the Centers for Disease Control and Prevention. Those who try to quit can double or triple their chances with counseling or medications, but most of those who did try to quit in 2010 didn’t use either. Nor did they receive advice on how to quit from a doctor. The findings suggest more needs to be done to help smokers quit — particularly certain segments of the population with low quit rates, said Tim McAfee, director of the public health agency’s Office on Smoking and Health, in an interview. Nearly 76% of African-American smokers wanted to quit last year, and 59% tried — well above the national average, said McAfee. But a mere 3.2% succeeded, which is the lowest rate among measured races and ethnicities. American smokers with college degrees had a far higher rate of success at quitting — 11.4% — than smokers with fewer than 12 years of schooling, who had only a 3.2% success rate. Still, McAfee said, there are some encouraging signs. For example, the percentage of young adults between the ages of 25 and 44 who want to [...]

Charlotte Parker2011-11-11T15:22:32-07:00November, 2011|Oral Cancer News|

Roger Ebert describes his cancer journey and a path to acceptance

The Guardian By Roger Ebert Guardian Note: Roger Ebert is regarded as one of the greatest film critics in the world. But after being diagnosed with thyroid cancer in 2002, he was left unable to speak, eat or drink. In an extract from his new book, Life Itself, he explains how his life has been changed. OCF Note: We highly recommend reading Mr. Ebert book "Life Itself". For those that read this news feed - whether you do as a dental or medical professional, or as a patient, survivor, or caregiver; it holds much wisdom that you can apply in your own world. Life Itself: A Memoir My secret as an interviewer was that I was actually impressed by the people I interviewed: not only by Bill Clinton, John Wayne or Sophia Loren, but by Sandra Dee, Stella Stevens and George Peppard. I am beneath everything else a fan. I was fixed in this mode as a young boy and am awed by people who take the risks of performance. I become their advocate and find myself in sympathy. I can employ scorched-earth tactics in writing about a bad movie, but I rarely write sharp criticism of actors themselves. If they're good in a movie, they must have done something right. If they're bad, it may have been the fault of the filming conditions or editing choices. Perhaps they may simply have been bad. I feel reluctant to write in a harmful way; not always, but usually. My job involved [...]

Charlotte Parker2011-11-09T17:29:52-07:00November, 2011|Oral Cancer News|

HPV Vaccination Could Reduce the Number of Screening Procedures

The National Journal By Sophie Quinton Widespread vaccination against cervical cancer could reduce the need for burdensome screenings, U.S. and Finnish researchers said on Tuesday. A study published in the journal Lancet Oncology show that GlaxoSmithKline’s Cervarix vaccine, which protects against two strains of human papillomavirus, or HPV, was more than 93 percent effective in preventing precancerous lesions in women who had never been infected and completely protected young women from the strains of virus targeted by the vaccine. The vaccine also reduced cancer risk for women who had already been infected by HPV, but was far less effective. A second study found that Cervarix can protect against rarer strains of HPV that also cause cancer. Neither study looked at Gardisil, the other licensed HPV vaccine, which protects against four strains of HPV—including the two targeted by Cervarix. The efficacy of vaccination adds fuel to two debates: how often women need to undergo cervical cancer screenings, and how important it is to reach girls—and boys—with HPV vaccinations before they become sexually active. The U.S. Preventive Services Task Force, American Cancer Society, and other clinical groups have agreed that the pap smear—the screening for cervical cancer—does not need to be done every year for most women, and suggest that screenings begin at age 21. For vaccinated women, the need for screening might be further reduced. “Provided that organised vaccination programs achieve high coverage in early adolescents before sexual debut, HPV vaccination has the potential to substantially reduce the incidence of cervical [...]

Charlotte Parker2011-11-08T20:47:32-07:00November, 2011|Oral Cancer News|

HPV vaccine may be as easy as just 1-2

Source: American Council on Science and Health Author: Staff Proven to be the leading cause of cervical cancer, the human papillomavirus (HPV) has recently been linked to anal and oral cancer as well. That’s why it’s important for young men and women to protect themselves against those strains of the virus with the HPV vaccine. Currently, the vaccine schedule consists of three shots that are spaced months apart, but unfortunately, a three-dose regimen may not be economically feasible for many. That’s why the results of a new study published in the Journal of the National Cancer Institute provide hope that receiving only two HPV vaccine doses — or even a single dose — may be enough to confer immunity. For the purposes of their study, researchers from the National Cancer Institute’s epidemiology division recruited 7,500 women between the ages of 18 and 25 who were HPV-negative; these women then received either three doses of the Cervarix vaccine against HPV, or a control (hepatitis A vaccine). Over a four year follow-up period, 929 women received only two doses of the vaccine, while 551 received only one. Surprisingly, the resistance to HPV infection among women who received two shots was just as high as it was among women who received all three shots. The study authors point out that a two-dose regimen has the potential to reduce cervical cancer incidence more effectively than the standard three-dose regimen since more women, especially in low-income regions, would opt to receive the shorter treatment regimen. The results, however, are [...]

Charlotte Parker2011-09-12T17:07:18-07:00September, 2011|Oral Cancer News|

Cancer drug resistance strategy uncovered

Source: Cancer Research UK Author: Staff Friday 9 September 2011- US scientists have identified a way in which cancer cells can become resistant to the cancer drug cetuximab (Erbitux), and suggest that treatments that are already available might be able to overcome this resistance. Researchers from the Dana-Farber Cancer Institute in Boston, US, have been studying why some patients only experience short-term benefits with cetuximab, or none at all. Cetuximab is an antibody that interferes with cancer cell growth. It can be given in combination with chemotherapy to patients with bowel cancer or head and neck cancer. Until now, scientists didn't know why some cancers failed to respond to the drug, or initially responded but then became resistant. The new study, published in Science Translational Medicine, found that in some of the drug-resistant cells, a protein known as ErbB2 (also known as HER2/neu) was sending 'grow' signals. These were bypassing the 'stop growing' signals caused by the drug. Pasi Janne, the study's co-senior author, said: "ErbB2 activates a critical signalling pathway that is not normally blocked by cetuximab, and in this way subverts cetuximab's function. "Because ErbB2 isn't affected by cetuximab, this is an easy way for cancers to become resistant to the drug." The researchers suggest that combining cetuximab with already available ErbB2 inhibitors such as trastuzumab (Herceptin) could produce an effective therapy to tackle cancers that previously showed resistance to cetuximab. Henry Scowcroft, science information manager at Cancer Research UK, said: "Unfortunately, patients's tumours can become resistant to treatment, and understanding why this happens is a [...]

Charlotte Parker2011-09-09T12:20:44-07:00September, 2011|Oral Cancer News|

Democrat Shelly Leonard, Former House District Candidate, Fights Cancer Again

Source: TampaBay By: Mike Brassfield, Times Staff Writer CLEARWATER — When she ran against incumbent state Rep. Ed Hooper last year, Shelly Leonard wasn't your typical candidate. She was a 37-year-old single mother — and a survivor of oral cancer. The feisty Democrat made her cancer history a part of her stump speech, talking about the need to make health insurance accessible to more people. "My tongue is scarred," she would say on the campaign trail, "but I have a strong voice." More than 16,000 people voted for her in Clearwater-based House District 50. But nearly 24,000 voted to keep Republican Hooper in office, so Leonard went back to her job as a social worker. Now she's facing some bad news. Leonard's oral cancer has returned. She's scheduled to undergo major surgery today at Moffitt Cancer Center in Tampa. "She's having surgery to remove four malignant tumors," said her friend and campaign treasurer, Van Farber. "After they remove the tumors, there's a question of how much of her tongue will be left after surgery — will she be able to talk in her normal voice, or just a whisper?" As tough as that is, it's actually an improvement over what her prognosis had been. As recently as six weeks ago, Leonard was told that her tumors were so large, she could lose part of her chin and some of her teeth and would need significant reconstructive surgery. "The most positive thing is, her tumors have shrunk since then," Farber said. [...]

Charlotte Parker2011-09-02T10:43:31-07:00September, 2011|Oral Cancer News|

Rate of HPV Vaccination in Teens Lagging

Source: The Associated Press Author: Staff Only about half of the teenage girls in the U.S. have rolled up their sleeves for a controversial vaccine against cervical cancer — a rate well below those for two other vaccinations aimed at adolescents. The vaccine hit the market in 2006. By last year, just 49 percent of girls had gotten at least the first of the recommended three shots for human papilloma virus, or HPV, a sexually-transmitted bug that can cause cervical cancer and genital warts. Only a third had gotten all three doses, the Centers for Disease Control and Prevention said Thursday. In contrast, the CDC said about two-thirds of teens had gotten the recommended shot for one type of bacterial meningitis and a shot for meningitis and tetanus, diphtheria and whooping cough. Granted, it can take many years for a new vaccine to catch on and reach the 90 percent and above range for many longstanding childhood vaccines. But use of HPV vaccine has been "very disappointing" compared to other newer vaccines, said the CDC's Dr. Melinda Wharton. "If we don't do a much better job, we're leaving another generation vulnerable to cervical cancer later in life," said Wharton. Why aren't more girls getting HPV shots? The vaccine can be very expensive, and it can be a bit of a hassle. It takes three visits to the doctor over six months. But sex no doubt has something to do with it, experts said. Girls are supposed to start the [...]

Charlotte Parker2011-08-26T12:24:52-07:00August, 2011|Oral Cancer News|

Life After Tongue Cancer, & a Total Glossectomy

Source: UCSF Medical Center Author: Sierra Tzoore Tongue cancer is uncommon, and it's especially unusual for it to strike a young person who doesn't smoke or drink heavily. Kate Brown was just 32 years old, recently married and beginning a new job, when she learned that a spot on her tongue was stage III tongue cancer. Brown was referred to UCSF Medical Center, where surgeons recommended a drastic treatment that was her best shot at survival: a total glossectomy, or tongue removal, followed by chemotherapy and radiation. Four years later, Brown is cancer-free and, unlike many patients who undergo total glossectomy, able to eat and speak understandably. We asked Brown about her treatment and path to recovery. How did you discover you had tongue cancer? A small sore appeared on my tongue when I had a sore throat. I took antibiotics for the sore throat, but the spot was still there after the sore throat subsided. I then started to have ear pain and the sore got larger. I was prescribed antibiotics again. When my doctor looked in my ear she didn't see any swelling, but the earache became unbearably painful. I'd never been in pain like that. In my heart of hearts, I knew at that point that something was terribly wrong, but I wasn't sure what it was. I decided to see another doctor, who referred me to an ear, nose and throat specialist, Dr. Ivor Emanuel at California Pacific Medical Center. Dr. Emanuel's specialty is allergies but I think [...]

Charlotte Parker2011-08-22T12:33:47-07:00August, 2011|OCF In The News, Oral Cancer News|

Resveratrol Selectively Induces DNA Damage, Independent of Smad4 Expression, in Its Efficacy against Human Head & Neck Squamous Cell Carcinoma

Source: Clinical Cancer Research Author: Robert A. Sclafani, University of Colorado School of Medicine, Campus Box 8101, Room 9100, Aurora, CO 80045. Phone: 303-724-3271; Fax: 303-724-3215; E-mail:[email protected] Abstract Purpose: Alterations in Smad4 signaling and its loss cause genomic instability and head and neck squamous cell carcinoma (HNSCC), suggesting that agents that target both Smad4-dependent and -independent pathways could control HNSCC. Experimental Design: Resveratrol efficacy was evaluated against the HNSCC cells FaDu, Cal27, Det562, and Cal27-Smad4 for viability, DNA damage, cell-cycle progression, and apoptosis, as well as γ-H2AX expression, and focus formation (γ-H2AX and Brca1). Resveratrol efficacy was also examined in nude mice for FaDu xenograft growth. Xenografts were analyzed for γ-H2AX and cleaved caspase-3. Results: Resveratrol (5–50 μmol/L) suppressed viability and induced DNA damage in FaDu and Cal27 cells but not in normal human epidermal keratinocytes and human foreskin fibroblasts, showing its selectivity toward HNSCC cells; however, Det562 cells were resistant to resveratrol even at 100 μmol/L. Cal27 cells stably transfected withSmad4 showed similar resveratrol effects as parental Cal27, indicating that a lack of resveratrol effect in Det562 cells was independent of Smad4 status in these cells. Furthermore, resveratrol caused S-phase arrest and apoptotic death of FaDu and Cal27 cells together with induction of Brca1 and γ-H2AX foci. Resveratrol (50 mg/kg body weight) treatment also inhibited FaDu tumor growth in nude mice, and γ-H2AX and cleaved caspase-3 were strongly increased in xenografts from resveratrol-treated mice compared with controls. Conclusion: Our findings for the first time showed antiproliferative, DNA damaging, and apoptotic effects of resveratrol in [...]

Charlotte Parker2011-08-15T10:20:48-07:00August, 2011|Oral Cancer News|

Laser Surgery On Tongue Cancer Successful for Aerosmith Musician

Source: KSAT Author: Brian Mylar Aerosmith Musician Shows Progress Fighting Cancer SAN ANTONIO -- Aerosmith will be performing in Mexico and South America this fall and one of the band members will be along for the tour thanks to a radical medical procedure. In one Aerosmith song, bassist Tom Hamilton sends a message to his throat and tongue cancer with the lyrics "you've got no business with me." Five years ago, Hamilton underwent chemotherapy and radiation for tongue-base cancer, but it came back and extended into his voice box. That is when he turned to Dr. Steven Zeitels. "This is not your classic way, or even traditional way, to try and remove a cancer from the tongue base," Zeitels said. Radical surgery was now Hamilton's only option. But that could leave his voice and breathing passage permanently damaged. "I was just terrified," Hamilton said. "I really though, 'Oh, I am looking at not being able to talk.'" Zeitels has treated vocal cord cancer with the green-light KTP laser, so Hamilton agreed to be the first person treated that way for tongue base cancer. The laser emits a green light, which is concentrated in the extra blood running through the cancer. "Where there is a lot of cancer, there will be a lot of blood," Zeitels said. "Where there is a lot of blood, there will be a lot of combustion so that you are actually watching the tissues burn completely different" But not everyone is a candidate for this surgery. [...]

Charlotte Parker2011-08-08T16:41:44-07:00August, 2011|Oral Cancer News|

Oral Cancer News
Compiled by The Oral Cancer Foundation

About Charlotte Parker